Navigation Links
Inostics' Blood-based Mutation Testing Receives CLIA Certification
Date:5/30/2013

BALTIMORE, May 30, 2013 /PRNewswire/ --

Inostics, a molecular diagnostics company that provides blood-based mutation testing, received CLIA (Clinical Laboratory Improvement Amendments) licensure for its clinical laboratory located in Baltimore, MD. This marks a critical milestone for the clinical adoption of this non-invasive molecular approach for the analysis of tumor biomarkers.

"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making. We are extremely excited to be able to bring this solution to cancer patients as OncoBEAM tests offer a significant enhancement to clinical care over traditional tissue-based molecular testing," Dr. Frank Diehl , CSO of Inostics, said.

The OncoBEAM blood test is based on BEAMing technology which combines emulsion based digital PCR with flow cytometry. This technology enables the molecular analysis of tumor DNA shed from primary and metastatic tumors, found circulating in the blood of patients. Due to its non-invasiveness, OncoBEAM blood tests introduce new possibilities for the management of various cancers like skin, colorectal, breast, and lung cancer. Now a simple blood draw can support clinical decision making in the context of therapy selection, assessment of drug response, resistance and recurrence monitoring, and detection of minimal residual disease (MRD).  

About Inostics

Inostics is a molecular service company whose core competency is mutation detection utilizing highly sensitive technologies such as BEAMing and Plasma-Sequencing. In addition to the CLIA services, Inostics serves pharmaceutical companies and researchers with testing services for plasma/serum and tissue samples in the field of clinical trials and research in oncology. Inostics' headquarters are located in Hamburg, Germany and Inostics Clinical Laboratory is located at the Science and Technology Park at Johns Hopkins in Baltimore, Maryland.

For more information on OncoBEAM blood testing and the BEAMing technology refer to http://www.clinical.inostics.com or email lab@inostics.com.

Press contact:
Inostics
Friederike Lehmann , PhD
Marketing & Licensing
Phone +49-(0)40-413383-90
Fax +49-(0)40-413383-99
lehmann@inostics.com
http://www.inostics.com


'/>"/>
SOURCE Inostics GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inostics DNA Blood Test Provides a More Precise Picture of Resistance Mutations Than Traditional Biopsies
2. DioGenix and Fast Forward Collaborate to Develop Blood-Based Molecular Diagnostic for Multiple Sclerosis
3. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
4. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
5. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
6. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
7. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
8. Trovagene to Introduce First Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring
9. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
10. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
11. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/5/2017)... CINCINNATI , June 5, 2017 The ... a brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Cincinnati Enquirer . Results are based on ... specializing in organizational health and workplace improvement. The survey measures ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology:
(Date:6/26/2017)... , ... June 26, 2017 , ... ... in the country, today announced the hiring of Richard Robinson as chief operating ... leadership and operations experience, with a proven track record of simplifying business processes ...
(Date:6/26/2017)... , ... June 26, 2017 , ... ... staff, and consumers are seeing lots of red these days. According to recent ... charges that result from medical coding errors(1). Some studies point to Electronic Health ...
(Date:6/25/2017)... ... ... Create a feel-good lyric music video in Final Cut Pro X with ProLyric from Pixel ... in the lyrics to any song. ProLyric flies in the text for each section and ... be added modularly for optimal control. ProLyric makes editing any music video or text-based production ...
(Date:6/25/2017)... ... 25, 2017 , ... With a heatwave currently bearing down on Northern California pushing temperatures to ... Being swimsuit ready is easy with laser hair removal. , The process of summer ... burdensome routine when all you want to do is get out, dive in and cool ...
(Date:6/24/2017)... Ronkonkoma, New York (PRWEB) , ... June 24, ... ... now joined the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, ... also open evenings and weekends so that visits to the dentist fit into ...
Breaking Medicine News(10 mins):